Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124


Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes.

Jäger D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A, Jäger E.

Cancer Immun. 2005 Dec 12;5:11.


Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1.

Wang W, Epler J, Salazar LG, Riddell SR.

Cancer Res. 2006 Jul 1;66(13):6826-33.


Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A.

J Exp Med. 1998 Jan 19;187(2):265-70.


Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.

Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.

Cancer Res. 2000 Aug 15;60(16):4499-506.


Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.

Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D.

J Immunol. 2000 Dec 15;165(12):7253-61.


Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.

Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A.

Cancer Immun. 2002 Sep 19;2:12.


The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.

Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF.

Clin Cancer Res. 2004 Oct 15;10(20):6946-55.


Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library.

Jäger D, Stockert E, Güre AO, Scanlan MJ, Karbach J, Jäger E, Knuth A, Old LJ, Chen YT.

Cancer Res. 2001 Mar 1;61(5):2055-61.


[Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].

Qiao H, Qian XP, Zhang HG, Tian C, Chen WF.

Beijing Da Xue Xue Bao. 2005 Dec 18;37(6):565-8. Chinese.


Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.

Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M.

Cancer Immun. 2003 Dec 17;3:18.


Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.

Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, Ishihara Y, Itoh K.

Clin Cancer Res. 2004 Sep 1;10(17):5828-36.


Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.

Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.

Cancer Res. 2004 Apr 1;64(7):2610-8.


NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.

Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A.

Clin Cancer Res. 2004 Apr 15;10(8):2879-90.


Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression.

Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jäger D, Chen YT, Mackay A, O'Hare MJ, Old LJ.

Cancer Immun. 2001 Mar 30;1:4.


Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.

Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.

Clin Cancer Res. 2005 May 1;11(9):3446-54.


Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.

Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T.

Breast Cancer Res Treat. 2004 Nov;88(1):29-41.


Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.

Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2003 Dec;52(12):771-9. Epub 2003 Sep 10.


Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.

Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C.

Cancer Res. 2003 Oct 15;63(20):6948-55.

Supplemental Content

Support Center